Our Mission
The mission of the National Association for Psychedelic Research (NAPR) is to empower individuals through education, research, advocacy, and community engagement. This organization is dedicated to delivering educational programs, promoting rigorous scientific research, advocating for policy reforms related to the therapeutic and responsible use of psychedelics, with the aim of advancing mental health and wellbeing.
Our Vision
NAPR' vision is to create a world where psychedelics are recognized and accepted as an effective tool for promoting mental health and well-being. The organization strives to make psychedelics accessible and safe for therapeutic use, support continuous research on the potential of psychedelics, and build a supportive and educated community that shares knowledge and experiences.
Activities
Education
The National Association For Psychedelic Research is dedicated to providing educational programs, seminars, workshops and conferences. Our primary goal is to inform professionals and the general public about psychedelics and their potential for improving mental health.
Advocacy
Active engagement in advocating for policy changes that would allow access to strictly controlled therapeutic use of psychedelics. We believe that it is important to support innovative therapeutic approaches and that people should be given choice in their treatment process.
Community support
Organization of meetings, group discussions, exchange of knowledge and experiences to provide support to experts, psychiatrists, psychotherapists and individuals who are interested in the potential of psychedelics in improving mental health. Our goal is to create a supportive community that shares resources and supports each other.
Research
Promotion of scientific research related to psychedelics and their use in therapy and improvement of mental health. Advocating for rigorous research methodologies and promoting high ethical standards in this area, in order to provide relevant and reliable information.
The use of psychedelics in research for various disorders
Reference: Kurtz, J. S. et al. (2022). The use of psychedelics in the treatment of medical conditions. Cureus. doi.org/10.7759/cureus.29167
Anxiety 29%
PTSD 24%
Depression 23%
Addiction 15%
Headache 8%
Other 1%
PTSD
MDMA as part of the psychotherapy process shows extremely effective results in the treatment of PTSD. Studiesshow that a large number of participants no longer meet diagnostic criteria for PTSD after treatment.
ADDICTION
Psychedelics are being researched as an aid in the treatment of various forms of addiction – from nicotine and alcohol to opiates. Psilocybin, combined with psychotherapy, helps patients develop a deeper understanding of their behavior patterns and more easily make lasting changes.
ANXIETY
Psilocybin shows significant potential in reducing anxiety symptoms, especially in patients facing terminal illnesses. Studies indicate that one or two therapeutically guided experiences can contribute to long-lasting positive changes in emotional experience.
DEPRESSION
In clinical trials, psilocybin led to significant improvement in people with severe depression, including cases resistant to standard antidepressants. Changes in thought patterns, which often occur during and after a psychedelic experience, contribute to the reduction of depressive symptoms.
HEADACHE
Although in the early stages of research, microdosing of LSD and psilocybin shows potential in alleviating cluster headaches – a form of chronic pain that significantly impairs patients' quality of life.
OTHER
Obsessive-Compulsive Disorder (OCD)
Existential distress
Note: Psychedelics are used exclusively within clinical trials and under professional supervision. Self-initiated use of these substances can be dangerous and is subject to legal penalties. This section is intended for informational purposes only.
Insights & Research
The History Of Psychedelics
Albert Hofmann isolates psilocybin from magic mushrooms
1955
Complete regulation and prohibition of psychedelic use
1965-1970
1938
Albert Hofmann synthesizes LSD for the first time
1950s
Clinical psychiatry research
1960s
Psychedelics in counterculture
2000
Renewed global interest in psychedelics and revival of research
Today
The renaissance of psychedelic research
Write Us
If you’d like to collaborate with us, contact us at: info@nasp.org.rs or fill out the form.